256931-54-1

Basic information

• Product Name: 3-METHYL-3-AZETIDINOL
• Synonyms: 3-METHYL-3-AZETIDINOL;3-METHYLAZETIDIN-3-OL;3-Hydroxy-3-Methylazetidine
• CAS NO: 256931-54-1
• Molecular Formula: C₄H₉NO
• Molecular Weight: 87.12
• Mol File: 256931-54-1.mol

Chemical Properties

• Boiling Point: 157.366°C at 760 mmHg
• Flash Point: 89.622°C
• Appearance: /
• Density: 1.057g/cm³
• Vapor Pressure: 0.99mmHg at 25°C
• Refractive Index: 1.479
• Storage Temp.: Keep in dark place,Sealed in dry,Store in freezer, under -20°C
• PKA: 14.57±0.20(Predicted)
• CAS DataBase Reference: 3-METHYL-3-AZETIDINOL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHYL-3-AZETIDINOL(256931-54-1)
• EPA Substance Registry System: 3-METHYL-3-AZETIDINOL(256931-54-1)

Safety Data

• Hazardous Substances Data: 256931-54-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-METHYL-3-AZETIDINOL is used as a CDK2 inhibitor for the treatment of cancer. It targets and inhibits the activity of cyclin-dependent kinase 2 (CDK2), a protein that plays a crucial role in cell cycle regulation and is often overexpressed in various types of cancer. By inhibiting CDK2, 3-METHYL-3-AZETIDINOL can help prevent uncontrolled cell proliferation and the growth of cancerous tumors.
Additionally, 3-METHYL-3-AZETIDINOL is used as an IRAK4 inhibitor for the treatment of diseases related to interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 is a key signaling molecule involved in the innate immune response and has been implicated in the pathogenesis of various inflammatory and autoimmune diseases. By inhibiting IRAK4, 3-METHYL-3-AZETIDINOL can potentially modulate the immune response and provide therapeutic benefits for patients suffering from such conditions.

InChI:InChI=1/C4H9NO/c1-4(6)2-5-3-4/h5-6H,2-3H2,1H3

Upstream product

• 919357-57-6 1-benzyl-3-methyl-3-(trimethylsilyloxy)azetidine 
• 40320-63-6 1-benzhydryl-3-methylazetidin-3-ol 
• 1104083-23-9 tert-butyl 3-hydroxy-3-methylazetidine-1-carboxylate 

Downstream Products

• 1046469-06-0 1-{[(8S)-2,3-dimethyl-8-(2-methylphenyl)-3,6,7,8-tetrahydrochromeno[7,8-d]imidazol-5-yl]carbonyl}-3-methylazetidin-3-ol 
• 1428146-20-6 C₅₁H₅₇ClN₈O₆S₂ 
• 919357-37-2 1-(2,6-difluoro-4-nitrophenyl)-3-methylazetidin-3-ol 

Relevant articles and documents

As the NS4B inhibitor benzofuran analogs (by machine translation)

The present invention discloses a kind of as NS4B benzofuran analogue inhibitors, in particular to the formula (I) below or a pharmaceutically acceptable salt thereof. (by machine translation)

Tetrahydrochromenoimidazoles as potassium-competitive acid blockers (P-CABs): Structure-activity relationship of their antisecretory properties and their affinity toward the hERG channel

Potassium-competitive acid blockers (P-CABs) constitute a new therapeutic option for the treatment of acid-related diseases that are widespread and constitute a significant economical burden. Enantiomerically pure tetrahydrochromenoimidazoles were prepared using the readily available candidate 4 (BYK 405879) as starting material or the Noyori asymmetric reduction of ketones as key reaction. A comprehensive SAR regarding the influence of the 5-carboxamide and the 8-aryl residue on in vitro activity, acid-suppression in the Ghosh Schild rat, and affinity toward the hERG channel was established. In addition, efficacy and duration of the antisecretory action was examined for the most promising target compounds by 24 h pH-metry in the fistula dog and a significantly different SAR was observed as compared to the Ghosh Schild rat. Several tetrahydrochromenoimidazoles were identified that possessed a comparable profile as the candidate 4.

PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS

The present invention relates to novel compounds that are CGRP receptor antagonists, processes for their preparation, to compositions containing them and to their use in the treatment of migraine, headache, and cluster headache.

ENANTIOPURE PHARMACOLOGICALLY ACTIVE TRICYCLIC BENZIMIDAZOLES

The invention provides compounds of the formula (1) in which the substituents and symbols are as de fined in the description. The compounds inhibit the secretion of gastric acid.

OXAZOLIDINONES CONTAINING AZETIDINE AS ANTIBACTERIAL AGENTS

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R1 and R2 are independently H, F, OH, C1-2alkyl, CF3, OC1-2alkyl, optionally substituted